Related Experiment Video
Updated: May 13, 2026
07:31
A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
Origins of Montessori Programming for Dementia
1Hearthstone Alzheimer Care.
Non-Pharmacological Therapies in Dementia
|March 22, 2013
Summary
Montessori Programming for Dementia (MPD) adapts child education methods for dementia care, enhancing engagement and affect. This approach has shown international reach and potential for further research.
Area of Science:
- Gerontology
- Neuroscience
- Education
Background:
- Maria Montessori's educational methods, originally for children, are being adapted for cognitive interventions.
- The development of Montessori Programming for Dementia (MPD) is an autobiographical account of research efforts.
Purpose of the Study:
- To detail the evolution and application of Montessori educational methods for dementia interventions.
- To describe the translation of Montessori principles into activities for individuals with dementia.
- To present the dissemination and future research directions of MPD.
Main Methods:
- Adaptation of Montessori's educational philosophy and methods for persons with dementia.
- Development of observational assessment tools to measure engagement and affect.
- Documentation of MPD's use by researchers, staff, families, and persons with dementia.
Main Results:
- Montessori Programming for Dementia (MPD) has been successfully developed and applied.
- Observational tools effectively measure engagement and affect in dementia care settings.
- MPD has demonstrated international dissemination and diverse applications.
Conclusions:
- Montessori educational methods provide a viable framework for developing effective dementia interventions.
- MPD shows promise in enhancing the well-being and engagement of individuals with dementia.
- Further research is warranted to explore the full potential and applications of MPD.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...